Clinical trials: Pancreas Carcinoma
Pancreatic Adenocarcinoma Resectable
Adjuvant Pancreatic Therapy Guided by MRD
Pancreatic adenocarcinoma (PAAD) is a leading cause of cancer-related deaths worldwide. Although surgical resection can be curative, the 5-year overall survival (OS) rate after resection alone is approximately 20%.
- Trial name
- ADAPT-MRD (NCT06966440)
- Testing
- circulating tumor DNA (ctDNA)-based MRD, adjuvant chemotherapy regimens
- Where
- China
- Volunteers
- 856 people
- Sponsor
- Ruijin Hospital
Colorectal Cancer, Breast Cancer
QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.
This is a phase 1 study to evaluate the safety, the Recommended Phase 2 Dose (RP2D), and preliminary efficacy of a personalized neoepitope yeast-based vaccine, YE-NEO-001, in subjects who have completed potentially curative…
- Conditions
- Colorectal Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Melanoma
- Trial name
- NCT03552718
- Testing
- YE-NEO-001
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- NantBioScience, Inc.
Pancreatic Cancer, Malnutrition
Whipple Protein Study
Study investigators aim to assess the effect of providing high-protein nutritional supplementation before and after surgery
- Trial name
- WPS (NCT04306874)
- Testing
- Ensure Max Protein
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Thomas Jefferson University
Pancreatic Cancer
Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer
The purpose of this study is to compare the overall survival in patients with previously untreated metastatic pancreatic cancer receiving gemcitabine/nab-paclitaxel plus OGX-427 or gemcitabine/nab-paclitaxel plus placebo.
- Trial name
- Rainier (NCT01844817)
- Testing
- OGX-427
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- SCRI Development Innovations, LLC
Malignancy, Non-hodgkin Lymphoma
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of CYT-0851 in patients with…
- Conditions
- Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer
- Trial name
- NCT03997968
- Testing
- CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine
- Where
- 16 sites in United States
- Volunteers
- 169 people
- Sponsor
- Cyteir Therapeutics, Inc.
Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV
Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.
The purpose of this study is to determine the recommended dose of TBI-1401(HF10) treatment in combination with chemotherapy (Gemcitabine + Nab-paclitaxel or TS-1) in patients with stage III or IV unresectable pancreatic cancer.
- Trial name
- NCT03252808
- Testing
- TBI-1401(HF10), Gemcitabine, Nab-paclitaxel
- Where
- 8 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Takara Bio Inc.
Pancreatic Cancer, Adenocarcinoma
Pilot Study of Short-Course Preoperative Stereotactic Body Radiation Therapy for Resectable Pancreatic Cancer
The purpose of this study is to determine whether a short-course of stereotactic body radiotherapy (SBRT) prior to surgical resection of pancreatic adenocarcinoma is feasible and well-tolerated.
- Trial name
- NCT02347618
- Testing
- Preoperative SBRT
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Rochester
Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms
CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa)
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with limited therapeutic options and a five-year survival rate below 10 % in advanced stages.
- Trial name
- ResCPa (NCT07153289)
- Testing
- CD318-CAR-T cells
- Volunteers
- 38 people
- Sponsor
- University Hospital Tuebingen
Stage IV Pancreatic Cancer
Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca
The investigators recently completed a phase I study of intravenous ascorbic acid (IV AA) plus standard chemotherapy (gemcitabine and erlotinib) in patients with metastatic pancreatic cancer.
- Trial name
- NCT01555489
- Testing
- Ascorbic Acid
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Thomas Jefferson University
Cholangiocarcinoma, Pancreatic Ductal Adenocarcinoma
Short-term Starvation vs. Normal Diet Before Chemotherapy of Solid Tumors
Recent pre-clinical data provide strong evidence that short-term starvation before the administration of cytostatic drugs for the chemotherapy of solid tumors leads to significantly higher efficacy and lower toxicity levels.
- Conditions
- Cholangiocarcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Gastric Cancer
- Trial name
- NCT02607826
- Testing
- Starvation
- Volunteers
- 298 people
- Sponsor
- University Hospital Tuebingen
Pancreatic Cancer
Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients
This phase Ib study includes two phases: dose escalation phase and safety expansion phase. During the dose escalation phase, successive cohorts of eligible patients (minimum 3 and maximum 6 evaluable patients per cohort) will…
- Trial name
- NCT01487785
- Testing
- LDE225+gemcitabine
- Where
- 5 sites in United States, Spain and 1 more
- Volunteers
- 18 people
- Sponsor
- Novartis Pharmaceuticals
Stage IV Pancreatic Cancer
Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer
In this study we aim to test the efficacy of a combined and novel approach including induction chemotherapy (per standard of care) followed by SBRT and maintenance ipililumab + nivolumab in the first line setting of stage IV…
- Trial name
- NCT05088889
- Testing
- Nivolumab, ipilimumab, Stereotactic body radiation therapy
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Sheba Medical Center
Pancreatic Cancer
Use of Epidurals Intraoperatively for Patients Undergoing Pancreas Resection
The purpose of this study is to see if there is a difference in complications in patients who have an epidural started earlier (during their surgery) and used as part of the anesthetic in addition to using it for post operative…
- Trial name
- NCT03434678
- Testing
- Propofol+ Rocuronium+ Fentanyl 2 mcg/kg+ Inhalational Agent, Bupivacaine 0.125% + Fentanyl 5 mcg/ml, Propofol+ Rocuronium+ Fentanyl + Inhalational, Open Pancreaticoduodenectomy
- Where
- 3 sites in United States
- Volunteers
- 133 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
IRE
IRE After Chemotherapy for Locally Advanced Pancreatic Cancer
This is a prospective, randomized, controlled, exploratory Phase II clinical study. Approximately 60 eligible patients with locally advanced pancreatic cancer who have received three cycles of chemotherapy induction and have…
- Trial name
- NCT07799935
- Testing
- IRE
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer
CT-95 in Advanced Cancers Associated With Mesothelin Expression
This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with…
- Conditions
- Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced
- Trial name
- NCT06756035
- Testing
- CT-95
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- Context Therapeutics Inc.
Breast Cancer, Esophageal Cancer
Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells.
- Conditions
- Breast Cancer, Esophageal Cancer, Gastric Cancer, Lung Cancer
- Trial name
- NCT00003125
- Testing
- ALVAC-CEA vaccine, aldesleukin, sargramostim
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Georgetown University
Pancreatic Cancer
Adavosertib and Gemcitabine in Advanced Pancreatic
This study is being done to test the safety and effectiveness of combining Adavosertib and Gemcitabine in patients with pancreatic cancer. The names of the study drugs involved in this study are: Adavosertib Gemcitabine
- Trial name
- NCT05212025
- Testing
- Adavosertib, Gemcitabine
- Sponsor
- James Cleary, MD, PhD
Pancreatic Cancer, Stereotactic Body Radiation Therapy
Pilot Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic Cancer
The purpose of the phase I/II clinical study is to determine the best dose of fractionated stereotactic radiation therapy (SBRT) given either with Avasopasem manganese (GC4419) or placebo to patients who have been diagnosed with…
- Trial name
- NCT03340974
- Testing
- GC4419, Stereotactic Radiation Therapy (SBRT) 50 Gy, Stereotactic Radiation Therapy (SBRT) 55 Gy
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- Galera Therapeutics, Inc.
Pancreatic Neoplasms
A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the Body
The main purpose of this study is to evaluate the safety and side effects of LY2157299 in combination with gemcitabine in Japanese participants with pancreatic cancer that is advanced or has spread to another part of the body.
- Trial name
- NCT02154646
- Testing
- LY2157299, Gemcitabine
- Where
- 2 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Eli Lilly and Company
Metastatic Pancreatic Cancer
Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic Ductal Adenocarcinoma
This is a Phase I open labelled study to treat patients with metastatic pancreatic cancer with combination therapy using standard of care first line therapy with gemcitabine and nab-paclitaxel given days 1, 8, and 15 every 28…
- Trial name
- ProglumidePanc (NCT06017323)
- Testing
- Gemcitabine, Nab paclitaxel, Proglumide Dose level 1
- Where
- United States
- Sponsor
- Georgetown University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.